Moreover, targeting CXCR2+ immunosuppressive neutrophils, either independently or in combination with additional treatments, enhances antitumor immune activity; specifically, that of CD8+ T cells, and reduces tumor burden across different cancer types (48). Here, CXCR2 is linked to cancer.